Kidswell Bio Corporation
4584.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 2.17 | -0.04 | -0.76 | 0.53 |
| FCF Yield | 20.51% | -8.98% | -17.54% | -8.24% |
| EV / EBITDA | 29.06 | -3.91 | -14.48 | -25.81 |
| Quality | ||||
| ROIC | -0.24% | -38.74% | -17.14% | -26.75% |
| Gross Margin | 32.26% | 42.75% | 54.96% | 64.93% |
| Cash Conversion Ratio | -44.31 | 0.32 | 2.16 | 2.19 |
| Growth | ||||
| Revenue 3-Year CAGR | 22.33% | 15.71% | 40.71% | 13.37% |
| Free Cash Flow Growth | 305.07% | 68.08% | -21.50% | 7.95% |
| Safety | ||||
| Net Debt / EBITDA | -9.96 | -0.25 | -1.42 | 0.87 |
| Interest Coverage | 0.66 | -34.44 | -15.81 | -42.12 |
| Efficiency | ||||
| Inventory Turnover | 2.33 | 1.59 | 1.97 | 0.56 |
| Cash Conversion Cycle | 226.93 | 339.63 | 283.17 | 739.16 |